Recent Material Events - Maxygen, Inc (MAXY)

Filing Date	Description
2008-09-24	On September 18, 2008, Maxygen, Inc. (the “Company”) entered into a Co-Development and Commercialization Agreement (the “Agreement”) with Astellas Pharma Inc. (“Astellas”) relating to the development and commercializatio ...
2008-07-02	On July 1, 2008, Maxygen, Inc. (the “Company”) and its wholly owned subsidiaries, Maxygen Holdings Ltd. (“Holdings”) and Maxygen ApS, entered into a Technology Transfer Agreement (the “Technology Transfer Agreement”) wit ...
2008-06-13	An update regarding certain patent matters relating to the Company’s MAXY-G34 product candidate, which has been designed to be an improved version of long-acting G-CSF for the treatment of neutropenia and is currently in Phase II clinical trials ...
2008-05-09	On May 7, 2008, the Board of Directors of Maxygen, Inc. (the “Company”), based on the recommendation of the Compensation Committee, approved certain compensation arrangements for the executive officers of the Company. ...
2008-03-04	On February 27, 2008, Dr. Michael S. Rabson notified Maxygen, Inc. (the “Company”) of his decision to resign as General Counsel, Senior Vice President and Corporate Secretary, effective on or about March 31, 2008. ...
2008-02-12	On February 12, 2008, Maxygen, Inc. issued a press release announcing its financial results for the three months and year ended December 31, 2007. A copy of the press release announcing these financial results and certain other information is attache ...
2007-12-04	On December 4, 2007, Maxygen, Inc. (the “Company”) issued a press release announcing that it has entered into a license agreement with sanofi Pasteur, the vaccines division of the sanofi-aventis Group, pursuant to which the Company has lice ...
2007-11-27	On November 26, 2007, the Board of Directors of Maxygen, Inc. (the “Company”) approved a plan to consolidate the Company’s research and development activities at its U.S. facilities in Redwood City, California. The consolidation will ...
2007-11-26	On November 26, 2007, Maxygen, Inc. (the “Company”) issued a press release announcing that the Company and F. Hoffmann-La Roche Ltd (“Roche”) have agreed to terminate the Collaborative Development and Commercialization Agreement, ...
2007-11-19	On November 19, 2007, Maxygen, Inc. (the “Company”) issued a press release announcing that it expects to recognize approximately $7 million in revenue in the fourth quarter of 2007 under its license agreement with Codexis, Inc. (“Codex ...